Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
7
1
2021
medline:
19
8
2021
entrez:
6
1
2021
Statut:
ppublish
Résumé
To discuss the currently available evidence about the use oritavancin and dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and for other potential indications. In this review, we briefly summarize the available data on efficacy (from randomized controlled trials) and on effectiveness and cure rates (from observational studies) pertaining to the use of oritavancin and dalbavancin either for ABSSSI or for other indications. Oritavancin and dalbavancin are valid options for outpatient therapy and early discharge in patients with ABSSSI, especially when adherence to oral therapy cannot be guaranteed or no oral choices are available. Furthermore, it is worth noting that a non-negligible portion (sometimes the majority) of oritavancin and dalbavancin use in available real-life experiences is for indications other than ABSSSI, especially for Gram-positive osteomyelitis and endocarditis. The number of studies on the use of long-acting lipoglycopeptides for these currently off-label indications is rapidly increasing and will help to further optimize the use of these peculiar antibiotics in the forthcoming future.
Identifiants
pubmed: 33405480
doi: 10.1097/QCO.0000000000000714
pii: 00001432-202104000-00006
doi:
Substances chimiques
Anti-Bacterial Agents
0
Lipoglycopeptides
0
Teicoplanin
61036-62-2
dalbavancin
808UI9MS5K
oritavancin
PUG62FRZ2E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-108Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Poulakou G, Giannitsioti E, Tsiodras S. What is new in the management of skin and soft tissue infections in 2016? Curr Opin Infect Dis 2017; 30:158–171.
Kaye KS, Patel DA, Stephens JM, et al. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. PLoS One 2015; 10:e0143276.
Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus . Ann Emerg Med 2008; 51:291–298.
Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168:1585–1591.
Bassetti M, Magnasco L, Del Puente F, Giacobbe DR. Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Curr Opin Infect Dis 2020; 33:110–120.
Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis 2016; 29:109–115.
Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract 19952015; 43:137–143.
Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70:859–886.
Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009; 53:918–925.
Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs 2007; 16:717–733.
Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program. Diagn Microbiol Infect Dis 2006; 54:149–153.
Mendes RE, Farrell DJ, Sader HS, et al. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals. J Antimicrob Chemother 2015; 70:498–504.
Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs 2015; 75:2073–2095.
Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 2020; 9:700.
Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents 2018; 51:571–577.
Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents 2019; 53:429–434.
Ciccullo A, Giuliano G, Segala FV, et al. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection 2020; 48:309–310.
Johnson JA, Feeney ER, Kubiak DW, Corey GR. Prolonged use of oritavancin for vancomycin-resistant enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis 2015; 2:ofv156.
Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis 2019; 6:ofy331.
Scoble PJ, Reilly J, Tillotson GS. Real-world use of oritavancin for the treatment of osteomyelitis. Drugs Real World Outcomes 2020; 7:46–54.
Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections. Infect Dis Ther 2016; 5:1–15.
Biavasco F, Vignaroli C, Lupidi R, et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997; 41:2165–2172.
Cooper RD, Snyder NJ, Zweifel MJ, et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) 1996; 49:575–581.
Domenech O, Francius G, Tulkens PM, et al. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochim Biophys Acta 2009; 1788:1832–1840.
Munch D, Engels I, Muller A, et al. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother 2015; 59:772–781.
Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012; 54: (Suppl 3): S214–S219.
Vidaillac C, Parra-Ruiz J, Rybak MJ. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis 2011; 71:470–473.
Mitra S, Saeed U, Havlichek DH, Stein GE. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections. Infect Drug Resist 2015; 8:189–197.
Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother 2015; 59:3365–3372.
Bassetti M, Peghin M, Castaldo N, Giacobbe DR. The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf 2019; 18:635–650.
Kmeid J, Kanafani ZA. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review. Core Evid 2015; 10:39–47.
Food and Drug Administration (FDA)ORBACTIV ® (oritavancin) for injection, for intravenous use. Full prescribing information. 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206334s003lbl.pdf . [Cited 8 December 2020].
European Medicines Agency (EMA). ORBACTIV ® . Annex I. Summary of product characteristics. 2015. Available at: https://www.ema.europa.eu/en/documents/product-information/orbactiv-epar-product-information_en.pdf . [Cited 8 December 2020].
Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015; 60:254–262.
Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370:2180–2190.
Bassetti M, Giacobbe DR, Peghin M, Irani P. A look at clinical trial design for new antimicrobials for the adult population. Expert Rev Clin Pharmacol 2019; 12:1037–1046.
Deck DH, Jordan JM, Holland TL, et al. Single-dose oritavancin treatment of acute bacterial skin and skin structure infections: SOLO trial efficacy by Eron severity and management setting. Infect Dis Ther 2016; 5:353–361.
Lodise TP, Redell M, Armstrong SO, et al. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. Open Forum Infect Dis 2017; 4:ofw274.
Corey GR, Loutit J, Moeck G, et al. Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by Gram-positive bacteria: summary of safety analysis from the phase 3 SOLO studies. Antimicrob Agents Chemother 2018; 62:e01919–17.
Belley A, Robson R, Francis JL, et al. Effects of oritavancin on coagulation tests in the clinical laboratory. Antimicrob Agents Chemother 2017; 61:e01968–16.
Anastasio PJ, Wolthoff P, Galli A, Fan W. Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther 2017; 6:115–128.
Brownell LE, Adamsick ML, McCreary EK, et al. Clinical outcomes and economic impact of oritavancin for Gram-positive infections: a single academic medical center health system experience. Drugs Real World Outcomes 2020; 7:13–19.
Co D, Roebuck L, VanLandingham J. Evaluation of oritavancin use at a community hospital. Hosp Pharm 2018; 53:272–276.
Estrada S, Lodise TP, Tillotson GS, Delaportas D. The real-world economic and clinical management of adult patients with skin and soft tissue infections (SSTIs) with oritavancin: data from two multicenter observational cohort studies. Drugs Real World Outcomes 2020; 7:6–12.
Helton B, MacWhinnie A, Minor SB, et al. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis. Drugs Real World Outcomes 2020; 7:20–29.
Lodise TP, Palazzolo C, Reksc K, et al. Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting. Open Forum Infect Dis 2019; 6:ofz475.
Redell M, Moeck G, Lucasti C, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis 2018; 5:ofy051.
Redell M, Sierra-Hoffman M, Assi M, et al. The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of Gram-positive infections. Open Forum Infect Dis 2019; 6:ofz479.
Whittaker C, Lodise TP, Nhan E, Reilly J. Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway. Drugs Real World Outcomes 2020; 7:30–35.
Stewart CL, Turner MS, Frens JJ, et al. Real-world experience with oritavancin therapy in invasive Gram-positive infections. Infect Dis Ther 2017; 6:277–289.
Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy 2018; 38:152–159.
Morrisette T, Miller MA, Montague BT, et al. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother 2019; 74:2405–2416.
Morrisette T, Miller MA, Montague BT, et al. Long-acting lipoglycopeptides: ‘lineless antibiotics’ for serious infections in persons who use drugs. Open Forum Infect Dis 2019; 6:ofz274.
Ahiskali A, Rhodes H. Oritavancin for the treatment of complicated Gram-positive infection in persons who inject drugs. BMC Pharmacol Toxicol 2020; 21:73.
Van Hise NW, Chundi V, Didwania V, et al. Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study. Drugs Real World Outcomes 2020; 7:41–45.
Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm 2008; 65:599–610.
Sosio M, Stinchi S, Beltrametti F, et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem Biol 2003; 10:541–549.
Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298–1303.
Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 2015; 4:245–258.
Ciabatti R, Malabarba A. Semisynthetic glycopeptides: chemistry, structure–activity relationships and prospects. Farmaco 1997; 52:313–321.
Pfaller MA, Mendes RE, Duncan LR, et al. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe. J Antimicrob Chemother 2018; 73:2748–2756.
Sader HS, Streit JM, Mendes RE. Update on the in vitro activity of dalbavancin against indicated species ( Staphylococcus aureus , Enterococcus faecalis , beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017–2019. Diagn Microbiol Infect Dis 2020; 99:115195.
Di Pilato V, Ceccherini F, Sennati S, et al. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. Diagn Microbiol Infect Dis 2020; 96:114901.
Fernandez J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis 2016; 85:449–451.
Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn Microbiol Infect Dis 2018; 90:58–63.
Silva V, Antao HS, Guimaraes J, et al. Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection. J Antimicrob Chemother 2020; 75:2182–2187.
Food and Drug Administration (FDA). DALBAVANCE ® (dalbavancin) for injection, for intravenous use. Full prescribing information. 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021883s003lbl.pdf . [Cited 10 December 2020].
Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009; 49:465–476.
European Medicines Agency (EMA). XYDALBA ® . Annex I. Summary of product characteristics. 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/xydalba-epar-product-information_en.pdf . [Cited 10 December 2020].
Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169–2179.
Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407–1415.
Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016; 62:545–551.
Gonzalez PL, Rappo U, Akinapelli K, et al. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs Context 2018; 7:212559.
Bai F, Aldieri C, Cattelan A, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther 2020; 18:1271–1279.
Dinh A, Duran C, Pavese P, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents 2019; 54:668–672.
Gonzalez J, Andrade DC, Niu J. Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multisite healthcare system. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa1732.
doi: 10.1093/cid/ciaa1732
Koziatek C, Mohan S, Caspers C, et al. Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit. Am J Emerg Med 2018; 36:1312–1314.
McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther 2020; 9:53–67.
Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in Gram-positive skin and soft tissue infection, bone and joint infection. Infection 2019; 47:1013–1020.
Nair T, Fitzgerald J, Ly B, Wallace MR. Dalbavancin as a cost effective antibiotic. Infect Dis (Lond) 2018; 50:75–76.
Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 2018; 67:795–798.
Almangour TA, Perry GK, Terriff CM, et al. Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis 2019; 93:213–218.
Bartoletti M, Mikus E, Pascale R, et al. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Resist 2019; 18:195–198.
Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect Dis Ther 2019; 8:171–184.
Bryson-Cahn C, Beieler AM, Chan JD, et al. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis 2019; 6:ofz028.
Buzón Martín L, Mora Fernandez M, Perales Ruiz JM, et al. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study. Rev Esp Quimioter 2019; 32:532–538.
Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol Antimicrob 2019; 18:30.
Morata L, Cobo J, Fernandez-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother 2019; 63:e02280–18.
Streifel AC, Sikka MK, Bowen CD, Lewis JS 2nd. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents 2019; 54:652–654.
Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in Gram-positive infections. Int J Infect Dis 2019; 81:210–214.
Almangour TA, Perry GK, Alhifany AA. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study. Saudi Pharm J 2020; 28:460–464.
Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Perez S, et al. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm 2020; doi: 10.1136/ejhpharm-2020-002315.
doi: 10.1136/ejhpharm-2020-002315
Durante-Mangoni E, Boccia F, Ursi MP, et al. Dalbavancin for infective endocarditis: a single centre experience. J Chemother 2020; doi: 10.1080/1120009X.2020.1823119.
doi: 10.1080/1120009X.2020.1823119
Hitzenbichler F, Mohr A, Camboni D, et al. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source – a series of four cases. Infection 2020; doi: 10.1007/s15010-020-01526-0.
doi: 10.1007/s15010-020-01526-0
Núñez-Núñez M, PharmD M, Casas-Hidalgo I, Garcia-Fumero R, et al. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 2020; 27:310–312.
Vazquez Deida AA, Shihadeh KC, Preslaski CR, et al. Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy. Open Forum Infect Dis 2020; 7:ofaa293.
Veve MP, Patel N, Smith ZA, et al. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. Int J Antimicrob Agents 2020; 56:106210.
Redell M. Real-world evidence studies of oritavancin use in gram-positive infections augment randomized controlled trials to address clinical and economic outcomes. Drugs Real World Outcomes 2020; 7:2–5.
Turco NJ, Kane-Gill SL, Hernandez I, et al. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. Expert Opin Pharmacother 2018; 19:319–325.
Wilke M, Worf K, Preisendorfer B, et al. Potential savings through single-dose intravenous dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data. GMS Infect Dis 2019; 7:Doc03.